Moderna, Inc. (MRNA)
$
26.93
+0.88 (3.27%)
Key metrics
Financial statements
Free cash flow per share
-10.4249
Market cap
10.2 Billion
Price to sales ratio
3.2149
Debt to equity
0.0740
Current ratio
4.2182
Income quality
0.9091
Average inventory
122.5 Million
ROE
-0.3010
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Moderna, Inc., a biotechnology company focused on the discovery, development, and commercialization of messenger RNA therapeutics and vaccines, reports total costs and expenses amounting to $7,181,000,000.00 reflecting its overall spending in various therapeutic areas. The gross profit ratio stands at 0.55 highlighting the efficiency of the company's production and sales operations. Additionally, the cost of revenue for the company is $1,464,000,000.00 showcasing its production and operational expenses in delivering a range of vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases both in the United States and internationally. The diluted EPS is -$9.27 accounting for potential share dilution, and the company reported selling, general, and administrative expenses of $1,174,000,000.00 indicating its operational overhead costs necessary for supporting its innovative research and development efforts. In terms of investment potential, the stock is affordable at $26.05 making it suitable for budget-conscious investors. With a high average trading volume of 10,683,683.00 the stock indicates strong liquidity, allowing for ease of trading. Moderna holds a mid-range market capitalization of $10,414,962,060.00 which signifies it as a steady performer within the biotechnology field. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving forward advancements in therapeutic options. Furthermore, the company operates within the Healthcare sector, fostering innovation and growth that are essential in addressing both existing and emerging health challenges.
Is Moderna, Inc. (MRNA) a good investment?
Investing in Moderna, Inc. (MRNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Moderna, Inc. (MRNA)'s stock forecast?
Analysts predict Moderna, Inc. stock to fluctuate between $23.15 (low) and $158.82 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Moderna, Inc.'s market capitalization?
As of 2025-05-29, Moderna, Inc.'s market cap is $10,414,962,060, based on 386,742,000 outstanding shares.
How does Moderna, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Moderna, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Moderna, Inc. (MRNA) stock?
To buy Moderna, Inc. (MRNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for MRNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Moderna, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Moderna, Inc. perform in the last earnings report?
Revenue: $3,236,000,000 | EPS: -$9.27 | Growth: -24.88%.
Where can I find Moderna, Inc.'s investor relations reports?
Visit https://www.modernatx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Moderna, Inc.?
You can explore historical data from here
What is the all-time high and low for Moderna, Inc. stock?
All-time high: $497.49 (2021-08-10) | All-time low: $23.15 (2025-04-07).
What are the key trends affecting Moderna, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Moderna, Inc. (NASDAQ:MRNA ) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Courtney Breen So I am thrilled to be here today with Stephane Bancel from Moderna. My name is Courtney Breen.
reuters.com
The Trump administration has cancelled a contract awarded to Moderna for the late-stage development of its bird flu vaccine for humans, as well as the right to purchase shots, according to the drugmaker.
accessnewswire.com
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype.
zacks.com
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
forbes.com
Moderna (NASDAQ: MRNA) has caught the market off guard with a significant recovery in recent days – reaching current levels of approximately $27 after hitting a five-year low of $23.15 last week – following the FDA's decision to continue advising annual COVID-19 vaccinations for high-risk populations. However, this abrupt rally appears to be a singular occurrence – competitors such as Pfizer (NYSE: PFE), Sarepta Therapeutics (NASDAQ: SRPT), and CureVac (NASDAQ:CVAC) did not replicate Moderna's increase – implying the rise was primarily fueled by the FDA guidance rather than a wider sector uptrend.
reuters.com
Moderna said on Friday it had filed a marketing application for an updated COVID vaccine to the U.S. Food and Drug Administration.
accessnewswire.com
CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant.
zacks.com
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
marketbeat.com
Moderna Inc. NASDAQ: MRNA is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 months.
zacks.com
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
See all news
